Daré Bioscience (DARE) Resumen de Acciones
Daré Bioscience, Inc. desarrolla terapias en los ámbitos de la anticoncepción, el dolor pélvico, la fertilidad, las enfermedades infecciosas, la menopausia y la salud sexual y vaginal en Estados Unidos. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 0/6 |
| Crecimiento futuro | 5/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
DARE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Daré Bioscience, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$2.17 |
| Máximo en las últimas 52 semanas | US$9.19 |
| Mínimo de 52 semanas | US$1.27 |
| Beta | 1.09 |
| Cambio en 1 mes | 21.23% |
| Variación en 3 meses | 27.65% |
| Cambio de 1 año | -24.91% |
| Variación en 3 años | -82.44% |
| Variación en 5 años | -86.09% |
| Variación desde la OPV | -96.99% |
Noticias y actualizaciones recientes
Recent updates
Women’s Health Pipeline Risks Will Persist Yet Long Term Potential Will Eventually Emerge
Catalysts About Daré Bioscience Daré Bioscience develops women’s health products across sexual health, contraception, menopause, vaginal health and infectious disease, with a focus on differentiated formulations built around known compounds. What are the underlying business or industry changes driving this perspective?
Women’s Health Pipeline And Dual 503B Pathway Will Transform Long Term Earnings Potential
Catalysts About Daré Bioscience Daré Bioscience focuses on developing and commercializing women’s health products across sexual health, contraception and menopause. What are the underlying business or industry changes driving this perspective?
Women’s Health Platform And 503B Launches Will Reshape Long-Term Outlook
Catalysts About Daré Bioscience Daré Bioscience is a women's health company focused on developing and commercializing clinically supported products across sexual health, contraception, menopause and vaginal health. What are the underlying business or industry changes driving this perspective?We're A Little Worried About Daré Bioscience's (NASDAQ:DARE) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Is Daré Bioscience (NASDAQ:DARE) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Daré rises on positive data from early-to-mid-stage trial of intravaginal ring to treat menopause symptoms
Daré Bioscience (NASDAQ:DARE) is trading 6.5% higher after the company announced positive data from its Phase 1/2 clinical trial of investigational intravaginal ring, DARE-HRT1, to treat the vasomotor symptoms and genitourinary syndrome associated with menopause. The drug is designed to deliver bio-identical 17β-estradiol and bio-identical progesterone continuously over a 28-day period as part of a hormone therapy regimen. The topline data from the study showed improvement in both vasomotor symptoms as well as vaginal symptoms of menopause. The primary objective or the main goal of the study was to demonstrate the safety, tolerability, and pharmacokinetics (PK) of two different dose combinations over 12 weeks of use. The company said the levels of estradiol released from both the lower and higher dose formulation of DARE-HRT1 evaluated in the study achieved statistically significant improvement. Menopausal symptoms, including hot flashes and night sweats, were reduced compared with baseline in both DARE-HRT1 dose groups. The topline PK data from the study will be available later in Q4.Daré Bioscience rises as company submits application to begin trial of non-hormonal contraceptive
Daré Bioscience (NASDAQ:DARE) is trading 5.3% higher after the U.S. Food and Drug Administration approved its investigational device exemption (IDE) application to conduct an efficacy study of investigational hormone-free monthly intravaginal contraceptive, Ovaprene. The IDE approval will mean the FDA determined that the company provided sufficient data to support the initiation and conduct of the study. The submission included the results of the postcoital test clinical study of Ovaprene, in which the therapy prevented sperm from entering the cervical canal across all women and all cycles evaluated. The company is targeting mid-year 2023 to begin study recruitment.Dare Bioscience reports positive progress for cream for female sexual arousal disorder
Dare Bioscience (NASDAQ:DARE) said that based on an interim analysis of phase 2b data for its sildenafil cream for female sexual arousal disorder, enrollment in the study will complete in Q4. Total enrollment will be 150 women. The company anticipates a top-line data announcement in Q2 2023. Sildenafil is the active ingredient in Viagra, a pill approved for erectile dysfunction. Dare (DARE) noted that its sildenafil cream is designed to be applied to the vaginal tissue just prior to intercourse to increase blood flow directly to the tissue. Seeking Alpha Quant Rating views Dare (DARE) as a hold with high marks for growth and revisions.Daré Bioscience signs agreement with Organon for bacterial vaginosis therapy
Women health firm Daré Bioscience (NASDAQ:DARE) announced an exclusive license agreement with clinical-stage biopharma firm Organon (NYSE:OGN) to commercialize Xaciato, DARE's treatment of bacterial vaginosis in patients 12 years of age and older. Under the agreement, Daré will receive a $10M upfront payment from Organon and is eligible to receive potential milestone payments of up to $182.5M and tiered double-digit royalties based on net sales. Xaciato will be commercially available in the U.S. in Q4, DARE said. The companies entered into the agreement on March 31.Will Daré Bioscience (NASDAQ:DARE) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Diving Back Into Daré Bioscience Again
Today, we revisit women's health concern Daré Bioscience for the first time in nearly a year. This small cap concern just received its first FDA approval and is advancing other candidates in its pipeline. A full investment analysis follows in the paragraphs below.We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Why Daré Bioscience, Inc. (NASDAQ:DARE) Could Be Worth Watching
While Daré Bioscience, Inc. ( NASDAQ:DARE ) might not be the most widely known stock at the moment, it led the NASDAQCM...Rentabilidad de los accionistas
| DARE | US Pharmaceuticals | Mercado US | |
|---|---|---|---|
| 7D | -21.1% | -13.2% | 1.1% |
| 1Y | -24.9% | 39.4% | 26.7% |
Rentabilidad vs. Industria: Los resultados de DARE fueron inferiores a los de la industria US Pharmaceuticals, que obtuvo un rendimiento del 39.4% el año pasado.
Rentabilidad vs. Mercado: DARE obtuvo unos resultados inferiores a los del mercado US, que fueron del 26.7% el año pasado.
Volatilidad de los precios
| DARE volatility | |
|---|---|
| DARE Average Weekly Movement | 21.9% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: El precio de las acciones de DARE ha sido volátil durante los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de DARE ha aumentado de 13% a 22% en el último año.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2015 | 23 | Sabrina Johnson | darebioscience.com |
Daré Bioscience, Inc. desarrolla terapias en las áreas de anticoncepción, dolor pélvico, fertilidad, enfermedades infecciosas, menopausia y salud sexual y vaginal en Estados Unidos. La empresa ofrece XACIATO, un gel antibacteriano de lincosamida para el tratamiento de la vaginosis bacteriana. También desarrolla Ovaprene, un anticonceptivo intravaginal mensual sin hormonas; Sildenafil Cream, una formulación en crema de sildenafil para administración tópica en los genitales femeninos para el tratamiento del trastorno de la excitación sexual femenina; DARE-HRT1 para tratar los síntomas vasomotores en la terapia hormonal de la menopausia; DARE-VVA1 para el tratamiento de la dispareunia o el dolor durante las relaciones sexuales; y DARE-HPV, una formulación de dosis fija de lopinavir y ritonavir en un gel vaginal blando para tratar la infección genital por el virus del papiloma humano (VPH), la neoplasia intraepitelial cervical y otras patologías relacionadas con el VPH.
Resumen de fundamentos de Daré Bioscience, Inc.
| Estadísticas fundamentales de DARE | |
|---|---|
| Capitalización bursátil | US$41.64m |
| Beneficios(TTM) | -US$13.40m |
| Ingresos (TTM) | US$1.03m |
¿Está DARE sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de DARE | |
|---|---|
| Ingresos | US$0 |
| Coste de los ingresos | US$0 |
| Beneficio bruto | US$0 |
| Otros gastos | US$0 |
| Beneficios | US$0 |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.92 |
| Margen bruto | 71.29% |
| Margen de beneficio neto | -1,300.66% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado DARE a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/15 01:44 |
| Precio de las acciones al final del día | 2026/05/15 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Daré Bioscience, Inc. está cubierta por 5 analistas. 2 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Brian Kemp Dolliver | Brookline Capital Markets |
| Douglas Tsao | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |